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Abstract
Acute kidney injury (AKI) is a syndrome that frequently affects the critically ill. Recently, an
increased number of dinucleotide repeats in the HMOX1 gene were reported to associate
with development of AKI in cardiac surgery. We aimed to test the replicability of this finding
in a Finnish cohort of critically ill septic patients. This multicenter study was part of the
national FINNAKI study. We genotyped 300 patients with severe AKI (KDIGO 2 or 3) and
353 controls without AKI (KDIGO 0) for the guanine–thymine (GTn) repeat in the promoter
region of the HMOX1 gene. The allele calling was based on the number of repeats, the cut
off being 27 repeats in the S–L (short to long) classification, and 27 and 34 repeats for the
S–M–L2 (short to medium to very long) classification. The plasma concentrations of heme
oxygenase-1 (HO-1) enzyme were measured on admission. The allele distribution in our
patients was similar to that published previously, with peaks at 23 and 30 repeats. The S-
allele increases AKI risk. An adjusted OR was 1.30 for each S-allele in an additive genetic
model (95% CI 1.01–1.66; p = 0.041). Alleles with a repeat number greater than 34 were sig-
nificantly associated with lower HO-1 concentration (p<0.001). In septic patients, we report
an association between a short repeat in HMOX1 and AKI risk.
Introduction
Acute kidney injury (AKI) is a multifactorial syndrome that frequently accompanies critical ill-
ness. In a Finnish intensive-care-unit (ICU) cohort, the incidence of AKI was 39% [1]. Clinical
risk factors alone fail to reliably predict the development and severity of AKI. Therefore, com-
mon genetic variants, genetic polymorphisms, have been studied in association with develop-
ment and outcome of AKI, but no conclusive evidence about the role of polymorphisms exists.
Disturbances in iron metabolism are associated with inflammation and oxidative stress and
have been suggested to participate in the pathogenesis of AKI [2–4]. A recent study presented
an association between a repeat polymorphism in the heme oxygenase-1 (HMOX1) gene and
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the development of AKI in adults undergoing cardiac surgery [5]. This dinucleotide (GTn,
guanine–thymine) repeat polymorphism in the promoter region of HMOX1 has been shown
to influence heme oxygenase (HO-1) levels [6,7]. Saukkonen and colleagues [6] have deci-
phered the reference range for HO–1 plasma concentration (0.66–2.39ng/mL) in 58 healthy
subjects. Moreover, they presented that the plasma concentrations of this ubiquitously
expressed enzyme are elevated in the critically ill [6].
In this study, we aimed to investigate whether the previously reported association between
HMOX1 repeat polymorphism and AKI development [5] can also be seen in our study popula-
tion of critically ill septic patients. Additionally, we sought to verify the impact of the polymor-
phism on their protein levels.
Materials and methods
Study population
This study was part of a national, multicenter, prospective, observational FINNAKI study con-
ducted in 17 Finnish ICUs in the years 2011–2012. The study population consisted of adult
Finns (>18 years). We enrolled all patients admitted due to emergency admission of any
expected length, as well as elective postoperative patients with an expected stay of>24 hours.
The current analysis included only patients with sepsis. Genetic samples were collected on
admission. A written informed consent was obtained from the patient or the next of kin as
soon as possible, however the initiation of the study for each participant was not delayed due
to the deferred consent procedure. In this procedure the participant was enrolled to the study
were there no exclusion criteria and the inclusion criteria were fulfilled on admission to the
ICU. Should the participant or the next of kin decline the study, the data gathered thus far
were removed. Exclusion criteria are listed in the supporting information (S1 Appendix). The
study was approved by the Ethics Committee of the Department of Surgery in Helsinki Uni-
versity Hospital and adheres to the Declaration of Helsinki.
Definitions
AKI was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria
[8]. To strengthen our findings, we defined the AKI phenotype as KDIGO stages 2 or 3, and
we chose to exclude patients with stage-1 AKI from the analysis [9]. We defined sepsis accord-
ing to American College of Chest Physicians/Society of Critical Care Medicine (ACCP/
SCCM) criteria [10].
Data collection
Database maintained by Finnish Intensive Care Consortium (FICC) collected and provided
routine data (Tieto Ltd, Helsinki, Finland). Moreover, on admission as well as daily for 5 days
we collected study-specific data in a standardized case report form (CRF). We measured
plasma creatinine daily and urine output hourly. An automated calculator provided the AKI
stage calculations continuously.
Genotype analysis
Blood samples for DNA extraction were collected on admission and after separation of plasma,
stored at –80˚C. DNA was isolated using a Chemagic 360 instrument (Perkin Elmer, Baeswei-
ler, Germany), based on magnetic bead technology. A Chemagic DNA Blood10k Kit was used
according to manufacturer’s instructions. DNA samples were diluted to 12ng/μl concentration
for genotyping.
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The GTn repeat sequence in the HMOX1 gene promoter was first amplified by polymerase
chain reaction (PCR) using a 5’FAM–labeled forward primer 5’–FAM–AGAGCCTGCAGCT
TCTCAGA–3’ and a reverse primer 5’–ACAAAGTCTGGCCATAGGAC–3’. The sizes of the
PCR products were determined with fragment analysis using an ABI3730xl DNA Analyzer
(Applied Biosciences, Thermo Fisher Scientific, Vernon Hills, IL). Allele calling was based on
the GeneMapper Software version 4 (Applied Biosciences, Thermo Fisher Scientific, Vernon
Hills, IL) and visual inspection of the data by two investigators (LV and MK). As quality con-
trol, 2 duplicate samples, and 2 water controls were included on each plate. Six (0.7%) samples
were discarded because of poor quality. As a further quality control step, the GT repeat num-
bers were verified by capillary sequencing of 15 homozygote samples.
The alleles were classified into genotype groups in two different ways, based on the fre-
quency distribution of the alleles, as previously described [5]. In the two–class classification,
27 repeats was used as the cutoff [5,11]: <27 repeats were designated short (S), whereas
alleles with �27 repeats were designated long (L). Accordingly, three distinct genotypes, SS,
SL, and LL, were used in the analyses. The minor allele (S) frequency was 0.35. We per-
formed an additional analysis using three length classes [6,12] for repeat classification
(S < 27 �M < 34 � L2, as separation for L), along with genotypes SS, SM, MM, SL2, ML2,
and L2L2.
HO–1 plasma concentrations
From ethylene diamine tetra acetate (EDTA) anticoagulated plasma collected on admission,
HO-1 enzyme concentration was measured using an enzyme–linked immunosorbent assay
(ELISA). The detailed description of the method and its quality control are provided in the
supporting information (S2 Appendix).
Power calculation
The original study demonstrating an association between HMOX1 GTn polymorphism and
cardiac surgery related AKI [5] reported odds ratios (OR) of AKI for L–allele 1.25 and for LL
genotype 1.58. Based on this study, we estimated that approximately 600 patients (300 without
AKI) would be an adequate sample size to provide an 80% power to detect an association with
a p-value significance level of 0.05. Retrospectively, with these odds ratio assumptions and the
sample size, allele frequency, as well as AKI incidence from our data, with a p-value of 0.05, the
power of our study setting with allelic test was 0.89 and with genotype test 0.83 (by Genetic
Power Calculator [13]).
Statistical methods
Statistical analyses for the demographic data and for the comparisons between genotype
groups were performed with SPSS Statistics version 22 (IBM Corp., Armonk, NY, USA). We
present OR (odds ratios) with 95% CIs (confidence intervals), using Fishers exact test, for cate-
gorical variables and Kruskal–Wallis test for continuous variables. We present Cochran–Armi-
tage test for trend for ordinal genotype trend test. We tested for Nagelkerke pseudo R2 for the
logistic regression model with covariates, and with the model including the genotype (see sup-
porting information (S3 Appendix)). Logistic regression with additive, recessive and dominant
genetic models were performed with PLINK software [14]. We considered p-values <0.05
significant.
HMOX1 polymorphism in septic AKI
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Results
Altogether 653 patients with sepsis were successfully genotyped for HMOX1-promoter poly-
morphism. Their demographic and clinical data are presented in Table 1. Of these patients,
300 had KDIGO stage 2 or 3 AKI and 353 did not have AKI (KDIGO stage 0) (Fig 1). Patients
with KDIGO stage 1 (N = 189) AKI were not included in the analyses.
The allele distribution of the GT repeats is shown in Fig 2 and is similar to previously
reported values. The most common alleles had 23 repeats (16.8%) and 30 repeats (48.5%).
Descriptive statistics
There were 70 patients with an SS genotype, 318 patients with an SL genotype, and 265 patients
with an LL genotype. Of these patients, 40 (57%) within SS, 148 (47%) within SL, and 112
(42%) within LL had KDIGO stage 2 or 3 AKI (Fig 3) (p for trend 0.034, Cochran Armitage
test for trend). When only the SS and LL genotypes were compared, the SS genotype had an
OR of 1.35 of AKI (95% CI 1.06–1.73, p = 0.031) (Fig 4).
The event rates by genotype according to the three–class repeat classification are presented
in Fig 5 (p for trend 0.029, Cochran Armitage test for trend). When genotypes with either one
or two long L2 alleles (� 34 repeats) were compared to all the other genotypes We found no
significant difference in incidence of AKI between these groups (NS, Fig 5).
The Nagelkerke R Square statistic for covariates alone was 0.126. When the two-class or
three-class classification genotype was added, the Nagelkerke value was 0.134 and 0.138,
Table 1. Demographic data.
Data available All patients (N = 653) No AKI (n = 353) AKI (n = 300) p-value
Age (Y) 653 63 (53–74) 63 (51–72) 64 (54–75) 0.055
Gender (male) 653 418 (64) 234 (66) 184 (61) 0.192
BMI (kg/m2) 651 26.5 (23.5–29.7) 26.0 (23.1–29.2) 27.3 (24.4–30.8) 0.001
Co–morbidities
Arterial hypertension 651 323 (50) 163 (46) 160 (53) 0.084
Diabetes 653 150 (23) 68 (19) 82 (27) 0.015
Arteriosclerosis 648 76 (12) 35 (10) 41 (14) 0.178
COPD 649 64 (10) 45 (13) 19 (6) 0.008
Chronic liver disease 647 42 (7) 18 (5) 24 (8) 0.151
Systolic heart failure 649 64 (10) 40 (11) 24 (8) 0.186
Thromboembolism 649 42 (7) 25 (7) 17 6) 0.524
Rheumatic disease 648 43 (7) 25 (7) 18 (6) 0.636
Baseline plasma creatinine (μmol/l) 653 79.0 (67.0–93.3) 80.0 (68.0–94.0) 77.2 (66.5–93.0) 0.341
Admission
Emergency 648 635 (98) 342 (98) 293 (98) 1.000
Operative 652 154 (24) 87 (25) 67 (22) 0.518
Cardiac surgery 653 12 (2) 8 (2) 4 (1) 0.561
SAPS II score 24h without renal and age points 649 25 (18–33) 24 (17–30) 26 (20–37) <0.0001
White blood cells, maximum (109/l) 584 11.9 (7.7–12.7) 11.7 (7.9–16.4) 12.2 (7.5–17.8) 0.450
Platelets, minimum (109/l) 632 189.5
(128.0–265.0)
196.0
(141.0–268.0)
184.0
(111.0–261.0)
0.040
Plasma bilirubin, maximum (μmol/l) 305 14.0 (7.0–25.5) 13.0 (7.0–22.0) 14.0 (8.0–32.0) 0.150
Continuous variables distribute non–normally and are reported as median (interquartile range) and categorical variables as number (percentage). Abbreviations: AKI,
acute kidney injury; BMI, body mass index; COPD, chronic obstructive pulmonary disease; SAPS, simplified acute physiology score.
https://doi.org/10.1371/journal.pone.0217291.t001
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respectively. The genotype groups did not differ in disease severity according to SAPS II score
without age and renal points (see supporting information (S4 Appendix) for detailed results).
Logistic regression
The S-allele was a minor allele with a frequency of 0.35 in the AKI patients, and the risk allele
for AKI. In an additive genetic model, each S-allele increased the risk of AKI with an OR of
1.29 (95% CI 1.02–1.64, p = 0.034). Adjustment for age, gender, body mass index (BMI), diabe-
tes, hypertension, chronic obstructive pulmonary disease (COPD), simplified acute physiology
score II (SAPS II) without points from age and kidney function, and platelet count, in multi-
variate logistic regression with additive genetic model did not change the direction or the mag-
nitude (OR 1.30, 95% CI 1.01–1.66; p = 0.041). The results for different genetic models are
presented in Table 2.
HO-1 plasma concentration analysis
Of the 653 patients, 601 (92%) were successfully sampled for HO-1 plasma concentration.
HO-1 was significantly higher in patients with AKI (2.2ng/mL vs 1.7ng/mL, p = 0.001). The
median plasma concentration of HO-1 did not differ according to HMOX1 repeat
Fig 1. Study flow chart. Abbreviations: FINNAKI, Finnish acute kidney injury; DNA, deoxyribonucleic acid; KDIGO, Kidney
Disease: Improving Global Outcomes; AKI, acute kidney injury.
https://doi.org/10.1371/journal.pone.0217291.g001
HMOX1 polymorphism in septic AKI
PLOS ONE | https://doi.org/10.1371/journal.pone.0217291 May 23, 2019 5 / 13
polymorphism genotype when the two-class repeat classification was used (p = 0.35, see sup-
porting information (S5 Appendix) for more detailed results). However, according to the
three-class repeat classification, the median HO-1 concentration differed between the geno-
types (p<0.001). The patients with at least one L2-allele had significantly lower median HO-1
concentration when compared to the other genotypes with no L2 alleles (1.0ng/mL vs 2.0ng/
mL, p<0.001). In addition, this finding is significant when only the patients without AKI
(1.0ng/mL vs 1.8ng/mL, p<0.001), and the slightly smaller (n = 277) group of patients with
AKI (1.0ng/mL vs 2.4ng/mL, p = 0.004) were analyzed separately (Fig 6).
Discussion
In critically ill septic patients we report that the S-allele (<27 repeats) in the HMOX1 promoter
region is associated with development of AKI. This finding is in contrast with that previously
reported for cardiac-surgery related AKI [5]. The longest repeats (>34) were significantly asso-
ciated with lower HO-1 concentrations.
Leaf et al. [5] previously reported an increasing number of repeats to correlate with an
increased risk of AKI in patients that had undergone cardiac surgery. In contrast, in our study
the greater number of repeats appeared rather to be protective (see Fig 4). However, the predis-
posing factors were different in our population. The patients in the study by Leaf et al. had
undergone cardiac surgery in cardiopulmonary bypass, omitting emergency surgery, whereas
patients in our septic cohort were critically ill septic patients. Additionally, the clinical end-
point of AKI was defined differently. In the study by Leaf the urine output criteria were not
Fig 2. Distribution of alleles with (GT)n repeats in patients with and without acute kidney injury (AKI). The number of repeats ranged from 16 to 39.
https://doi.org/10.1371/journal.pone.0217291.g002
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included, whereas in our study we chose to exclude patients with mild AKI (KDIGO stage 1)
to separate the phenotypes with and without AKI.
The frequency distribution of the dinucleotide repeats showed a bimodal figure with peaks
at 23 and 30 alleles (Fig 2), similar to what is presented in previous publications [5,6,15]. This
supports the validity of data. To classify the various alleles based on the repeat length, we used
the two-class repeat classification, according to the work by Leaf et al [5]. However, three clas-
ses have been used [6,12] and hence we made an additional analysis using this three-class
repeat classification. This augmented the possibility to detect the association between the very
long (>34 repeats) and AKI, which could have possibly driven the results of Leaf et al. No sig-
nificant associations were found in this additional analysis.
The HMOX1 promoter repeat polymorphism has been previously associated with critical
illness, as has the elevated plasma concentration of HO-1 enzyme [6,12]. The inverse associa-
tion between a HMOX1 promoter GTn repeat length polymorphism and the concentration of
its gene product, HO-1, has been established repeatedly: the longer the dinucleotide repeat the
less HO-1 produced [6,7,16]. Purine-pyrimidine alternating sequences like this have a struc-
ture of Z-potential DNA sequence, which is known to negatively affect transcriptional activity
[16,17]. The effect of the GTn repeat on gene inducibility by oxidant stress was reported in a
transient-transfection assay, concluding that the short repeat allele was more inducible and the
basal expression level was higher than in the long repeat allele [16]. We found an association
between low HO-1 concentration and very long (>34) repeats. This would concur that only
these very long alleles are transcriptionally less active.
HO-1 is an enzyme assisting cells in survival in relation to stress. In an energy-dependent
reaction catalyzing heme degradation, HO-1 functions to produce biliverdin along with free
iron (Fe) and carbon monoxide (CO) according to the formula: Heme b2+ + O2 +NADPH
Fig 3. Acute kidney injury (AKI) event rate according to genotype (SS, SL, or LL).
https://doi.org/10.1371/journal.pone.0217291.g003
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+ H+! Biliverdin + Fe2+ + CO + NADP+ + H2O. HO-1 plasma concentrations have been
shown to associate with cytoprotection in kidneys, but also in other organs [18]. This effect is
highly important in defending against exaggerated inflammatory reaction [19–22], but can be
inappropriate when found to assist the survival of malignant cell lines [23]. The regulation of
HO-1 expression differs between cell and tissue types [16].
In addition to cytoprotection, HO-1 has been found to have a contradicting role as a possi-
ble indicator of disease severity, associating with worse outcome in the critically ill [6] and
after out-of-hospital cardiac arrest (OHCA) [24]. It has been suggested that there may be an
optimal therapeutic range for HO-1 expression in critically ill patients [6,25,26], which could
explain the detrimental effects demonstrated with elevated HO-1 levels in this patient group.
Moreover, increased HO–1 concentrations are presented in association with AKI [27]. In
agreement, we found an indication that lower plasma HO-1 level is associated with a decreased
risk of AKI. Despite this, the role of the enzyme induction is commonly seen as protective
from AKI [28,29]. Nath et al. [30] published the very first evidence of kidney protection by
HO-1 induction already two decades ago, reporting their experiment in a murine model. The
function of HO-1 in the presence of critical illness in humans appears to be less simple than
that induced experimentally by models mimicking rhabdomyolysis or ischemia-reperfusion in
another species. Moreover, in mice the regulation of HMOX1 expression is different from that
of humans [26,31]. In the critically ill the increase in HO-1 plasma concentration is suspected
Fig 4. Odds ratio (OR) of acute kidney injury (AKI) according to genotype (SS, SL, or LL).
https://doi.org/10.1371/journal.pone.0217291.g004
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to represent an injury-repairing response against acute illness and thus indicate the magnitude
of the damage [6]. In summary, the role of HO-1 enzyme induction in relation to stress
remains nebulous [23].
Our study has many strengths. First, the patients have been prospectively and systematically
characterized and diagnosed. We defined AKI according to the KDIGO criteria, but the
KDIGO-stage-1 patients were omitted from the analysis. We considered that the phenotype of
these patients with mild AKI would differ from the more severe AKI, and hence including
them could result in biased results. Second, in our sample, both the cases and controls came
from the same study cohort and represent critically ill patients with sepsis. Third, we con-
firmed the reliability of the genotype calling by additional sequencing of 15 homozygote sam-
ples. Finally, we included both the two-class and the three-class classifications of allele length
in our analyses to achieve a comprehensive view, as both approaches have been utilized in pre-
vious studies [5,11,12].
Some limitations of our study need to be considered. First, although the power calculations
suggest that we had over 80% power to detect a true association, it might be considered
whether the odds ratios in the original work might be inflated and thus, our true power was
less than 80%.
Second, the median concentrations of HO-1 were low in comparison to previous studies in
septic patients. However, HO-1 levels differed significantly between AKI and no-AKI patients,
Fig 5. Acute kidney injury (AKI) event rate according to genotype; three-class classification. Allele lengths are: S<27 repeats, 27�M<34, L2�34. The
blue columns each illustrate the event rate within a genotype, whereas the orange columns illustrate the event rate in all the genotypes without a very long
allele in comparison to genotypes with one or more very long alleles.
https://doi.org/10.1371/journal.pone.0217291.g005
Table 2. Odds ratios for HMOX1 risk alleles and acute kidney injury in different genetic risk models.
AKI risk Unadjusted Adjusted
genetic model risk allele odds ratio (95% CI) p-value odds ratio (95% CI) p-value
additive S 1.292 (1.019–1.639) 0.034 1.296 (1.011–1.662) 0.041
recessive S 1.656 (1.004–2.733) 0.048 1.626 (0.962–2.746) 0.069
dominant S 1.284 (0.937–1.759) 0.119 1.301 (0.936–1.807) 0.117
Abbreviations: AKI, acute kidney injury; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0217291.t002
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as well as according to genotype in three-class classification, despite overall modest concentra-
tions. In addition, 52 (8.0%) genotyped patients lacked a plasma sample for enzyme concentra-
tion measurement. Finally, we excluded patients with chronic kidney disease (CKD) from the
analyses, and thus, our findings are not generalizable to patients with underlying CKD.
We present that in septic, critically ill patients, a small number of dinucleotide repeats in
the promoter sequence of HMOX1 are associated to the development of AKI. Recently, in a
phenotype of cardiac-surgery-associated AKI, the inverse association was reported. This find-
ing suggests that the distinction between separate phenotypes within the clinical syndrome of
AKI is essential when seeking pathophysiological insight into AKI.
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